HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2
Cassandra S.L. Ho, Alicia I. Tüns, Hans‐Ulrich Schildhaus, Marcel Wiesweg, Barbara M. Grüner, Balázs Hegedűs, Martin Schüler, Alexander Schramm, Sebastian Oeck
Topics & Concepts
Cancer researchIn vivoMedicinePharmacologyMAPK/ERK pathwaySignal transductionBiologyCell biologyBiotechnologyProtein Tyrosine PhosphatasesGlycosylation and Glycoproteins ResearchPI3K/AKT/mTOR signaling in cancer